Skip to main content

Table 2 Subgroup analyses of the objective remission rate and one-year survival based on the Apatinib dose

From: The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis

Outcomes

Subgroups

Number of included RCTs

Heterogeneity(I2)

Model

OR

95%CI

P

Objective remission rat

Apatinib dose≥600 mg/d

3

0%

Fixed

2.44

1.97~2.81

<0.001

Apatinib dose<600 mg/d

10

0%

Fixed

2.91

2.53~3.67

<0.001

One-year survival

Apatinib dose≥600 mg/d

2

0%

Fixed

2.69

2.04~2.89

<0.001

Apatinib dose<600 mg/d

5

16%

Fixed

2.17

1.89~2.55

<0.001